FDA rejects second Sarepta drug for Duchenne muscular dystrophy - STAT

1. FDA rejects second Sarepta drug for Duchenne muscular dystrophy  STAT
2. Sarepta shares are tanking after Duchenne drug setback  MarketWatch
3. Sarepta Stock Dives After FDA Rejects Its Duchenne Muscular Dystrophy Drug  Investor's Business Daily
4. Parents Push One Rare-Disease Drug Through FDA, Not Its Successor  Bloomberg
5. Sarepta Therapeutics stock plummets after FDA rejects its muscular dystrophy treatment  Yahoo Finance
6. View full coverage on Google News